Dr. Wyand and Dr. Vishal Bansal on Recovery Now: Why Concussion Treatment Needs to Evolve

Written By Holly Plante

CEO Dr. Michael Wyand and Co-Founder Dr. Vishal Bansal joined Recovery Now host Kim Justus to discuss the science behind OXE103, how Ghrelin works in the brain, and why current concussion treatment needs to evolve beyond "sit in front of the window and watch a squirrel."

The Phase 2a results showed an 85% responder rate versus 33% for standard care at the University of Kansas Medical Center. The next step is a 160-patient Phase 2b trial that could position OXE103 as the first FDA-approved treatment for persistent concussion symptoms.

Join the mission to bring the first FDA-approved treatment for persistent concussion symptoms to market. Visit our campaign page on StartEngine .

This Reg CF offering is made available through StartEngine Primary LLC, member FINRA/SIPC. This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment.

Holly Plante
Previous

Alex Smith on The Dan Patrick Show: "There Are No Approved Treatments for Concussions"
Next

Can Any Good Come from the NYC NFL Shootings?